Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, and preliminary imaging data have shown encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions.
The company believes this imaging approach could enhance development of MS therapies, including its investigational candidate Lucid-MS. For Lucid-MS, an Investigational New Drug (IND) submission for a Phase 2 trial was submitted to the FDA in March 2026. Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The imaging study's progress is a key step in validating a tool that could directly measure demyelination in living patients, potentially providing a more sensitive endpoint for clinical trials.
For more details on the announcement, refer to the full press release at https://ibn.fm/4IZ0y. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Quantum also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets an OTC version of UNBUZZD(TM), and receives royalty payments from sales. The company retains 100% of the rights to develop similar products for pharmaceutical and medical uses.